This is a working overview of actin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-07. Anything still debated is marked as such rather than presented as settled.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
==== Career and Technical Education (CTE) Program ==== The Technical Academy is a program that provides students with technical skills and knowledge. Benefits to students include gaining a foundation for a college major in a technical field, having access to a technical career after high school if college is postponed, and having access to a part-time technical job to help with college expenses. Locations:
== Most complicated pocket watches == The Vacheron Constantin Reference 57260 (2015) – 57 complications Patek Philippe Calibre 89 (1989) – 33 complications Patek Philippe Henry Graves Supercomplication (1933) – 24 complications
=== Inflammatory and immune-related diseases === Microbial therapeutics are being studied for the treatment of inflammatory and immune-related diseases, including inflammatory bowel disease (IBD), allergies, and autoimmune disorders. In these conditions, the immune system becomes overactive or poorly regulated, leading to chronic inflammation. Certain microorganisms can help reduce inflammation by promoting immune balance. For example, some gut microbes produce molecules that calm inflammatory immune responses or support immune cells that help prevent excessive inflammation. Researchers are also developing engineered microorganisms that can release anti-inflammatory substances directly at sites of inflammation, which may reduce side effects compared with treatments that affect the entire body.
The two major inactive metabolites are the N-dealkylation products (the carboxylic acid ID-20219 and the piperazine ID-11614), and a norbornane hydroxylated derivative of ID-20219 (ID-20220). Of lurasidone and its metabolites circulating in the blood, the native drug makes up 11%, the main active metabolite 4%, and the inactive carboxylic acids 24% and 11%, respectively. Several dozen metabolites have been identified altogether.:59–61 Biological half-life is given as 18 hours or 20 to 40 hours in different sources. 80% or 67% of a radiolabelled dose was recovered from the feces, and 9% or 19% from the urine.
Sources: en.wikipedia.org
The pickup models were built until 1991 for markets such as South Africa, Zimbabwe, and the Philippines. In South Africa, the little bakkie was sold as the "Mazda F-1000" or "F-1300". In Thailand, a version of the pickup was produced in small numbers until the late 1990s as the Familia Super Cab and Maxi Cab. Engines (export power outputs, DIN):
=== Bi–Bo === Klaus Biemann (1926–2016). Austrian chemist at MIT, the "father of organic mass spectrometry" and particularly noted for his role in advancing protein sequencing with tandem mass spectrometry. Member Natl. Acad. Sci. USA. Ethel Ronzoni Bishop (1890–1975). American biochemist and physiologist at Washington University in St. Louis who studied carbohydrate metabolism. Pamela J. Bjorkman (b. 1956). American biochemist at Caltech, who studies immune recognition of viral pathogens. Member Natl. Acad. Sci. USA. Elizabeth Blackburn AC FRS FAA FRSN (b. 1948). Australian-American biochemist, Nobel Laureate, co-discoverer of telomerase. Konrad Emil Bloch FRS (1912–2000). German-American biochemist at Harvard, who worked on the mechanism and regulation of cholesterol and fatty acid metabolism. Nobel Prize in Physiology or Medicine 1964. Elkan Blout (1919–2006). American biochemist at Harvard, who worked on peptide structure and conformation, including cyclic peptides. Member Natl. Acad. Sci. USA. David Mervyn Blow FRS (1931–2004). British X-ray crystallographer at Imperial College London, who worked on protein structure. Tom Blundell, FRS (b. 1942). British biochemist at the University of Cambridge, structural biologist, and science administrator. Aaron Bodansky (1887–1960). Russian-born American biochemist at the Hospital for Joint Diseases, New York, specializing in the area of calcium metabolism. Paul D. Boyer (1918–2018). American biochemist, at UCLA who studied ATP synthase. Nobel Prize in Chemistry in 1997. Member Natl. Acad. Sci. USA.
=== 2018–present: Business and continued television success === In December 2018, Kardashian became the brand ambassador of Burst Oral Care & performed corn test on the electric toothbrush. On June 14, 2019, Kylie Cosmetics launched their collaboration with Kardashian called Kylie Cosmetics x Koko Kollection. This marked their third collaboration, after previously launched special collection of lip products called Koko Kollection in 2016 and the second part in 2017. In August 2019, Kardashian announced she will become an executive producer for the new season of Twisted Sisters, an Investigation Discovery show, consisting of ten hour-long episodes following stories of sisters who turned on each other. In November 2019, Kardashian partnered with her sisters Kourtney and Kim to create three new perfumes (one for each sister) for Kim's brand KKW Fragrance. The collection introduces Pink Diamond (Khloé's fragrance), Yellow Diamond (Kourtney's fragrance) and pure Diamond (Kim's fragrance). Each scent is individually inspired by and unique to her, Kim, and Kourtney. In October 2020, it was announced she became the brand ambassador and co-owner of Kiwi collagen supplement company Dose & Co. In 2021, Kardashian and her family announced that their reality show, Keeping Up with the Kardashians, would be ending after twenty seasons and almost 15 years on air. In September 2021, Khloe Kardashian hosted a tournament for Candy Crush Saga, marking the game's first tournament. The tournament was held in-app from September 23 until October 7.
In November 2007, Merck agreed to pay $4.85 billion to settle most of the pending Vioxx lawsuits. The settlement required that claimants provide medical and pharmacy records confirming the occurrence of a heart attack, ischemic stroke, or sudden cardiac death; the receipt of at least 30 Vioxx pills within 60 days prior to the injury or death; and confirmation of Vioxx being used within 14 days of the Vioxx-related event. The settlement was generally viewed by industry analysts and investors as a victory for Merck, considering that original estimates of Merck's liability reached between $10 billion and $25 billion. As of mid-2008, when the plaintiff class had reached the threshold percentage required by Merck to go through with the settlement, plaintiffs had prevailed in only three of the twenty cases that had reached juries, all with relatively small awards. Merck has refused to consider compensation for Vioxx victims and their families outside the US. This is particularly true in the UK where there are at least 400 victims and the legal protection afforded to the victims and their families is particularly weak. According to internal e-mail traffic released at a later lawsuit, Merck had a list of doctors critical of Vioxx to be "neutralized" or "discredited". "We may need to seek them out and destroy them where they live," wrote an employee. A Stanford Medical School professor said that Merck was engaged in intimidation of researchers and infringement upon academic freedom.
== Hormonal immunotherapy == For more information on this topic, see Immunotherapy Hormonal stimulation of the immune system with interferons and cytokines has been used to treat specific cancers, including renal cell carcinoma and melanoma.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.